Esterase Inhibitor

Esterase Inhibitor - most related articles:

- Kalbitor, ecallantide, approved for treating hereditary angioedema - 4.7
- Complete response letter for Cinryze for hereditary angioedema - 3.8
- New drug reverses resistance to chemotherapy in pancreatic cancer patients - 3.5
- Proton pump inhibitors increase heart attacks in patients on clopidogrel - 2.9
- Novel approach to treat Alzheimer's disease - 2.8
- Ulcer medicines may lead to infections and fractures - 2.8
- Alzheimer's disease drug treats traumatic brain injury - 2.3
- Takeda's Uloric febuxostat approved for hyperuricemia in gout - 2.3
- Way to increase metabolism for weight loss - 2

Esterase Inhibitor articles

Complete response letter for Cinryze for hereditary angioedema
ViroPharma Incorporated (Nasdaq: VPHM) announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Esterase Inhibitor articles listed above.


Mission
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system.

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
5.58